Metiamide |
Catalog No.GC13024 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 34839-70-8
Sample solution is provided at 25 µL, 10mM.
Metiamide is a high-selective and oral bioavailable antagonist of histamine H2-receptor with ED50 value of 25 μmol/kg [1].
Unlike the traditional antihistaminics which are H1-receptor antagonists, metiamide is an antagonist of H2-receptor. It is developed from burimamide which is a previously found antagonist of H2-receptor. Metiamide acts as a competitive antagonist and blocks the combination of histamine and its receptor. This blockade results in the inhibition of gastric acid secretion stimulated by histamine and other hormone such as pentagastrin and gastrin. Compared with burimamide, metiamide showed higher activity and good oral bioavailability [1 and 2].
In the in vitro assays, metiamide displayed about 10-fold higher activity than burimamide on rat uterine muscle and guinea-pig heart muscle with Kb values of 0.75 and 0.92 μM, respectively. The Kb value of burimamide on the atrial muscle was 7.8 μM. Besides that, metiamide showed no efficacy on H1-receptor and isoprenaline even at the concentration of 1 mM suggested that metiamide was also a selective antagonist. Moreover, metiamide was found to cause increase in chemokinesis and random migration in PMN cells similar to histamine. It was different that metiamide had no effects on the true chemotaxis whereas histamine significantly suppressed the chemotaxis, which demonstrated histamine affected neutrophil motility through the H2-receptor site [1 and 3].
In dogs, the administration of metiamide inhibited acid secretion stimulated by histamine from both the Heidenhain pouch and the gastric fistula. It also inhibited acid secretion stimulated by pentagastrin and liver extract from both the Heidenhain pouch and the main stomach. When metiamide was given by intravenous injection, the doses of it to cause 50% inhibition of the maximal histamine- and pentagastrin-stimulated acid secretion were 3.1 and 6.1 μmol/kg. When metiamide was given by oral administration, the ED50 value of it to cause inhibition was 16 μmol/kg [1 and 2].
References:
[1] Black J W, Duncan W A M, Emmett J C, et al. Metiamide—an orally active histamine H2-receptor antagonist. Agents and Actions, 1973, 3(3): 133-137.
[2] Grossman M I, Konturek S J. Inhibition of acid secretion in dog by metiamide, a histamine antagonist acting on H2 receptors. Gastroenterology, 1974, 66(4): 517-521.
[3] Anderson R, Glover A, Rabson A R. The in vitro effects of histamine and metiamide on neutrophil motility and their relationship to intracellular cyclic nucleotide levels. The Journal of Immunology, 1977, 118(5): 1690-1696.
Cas No. | 34839-70-8 | SDF | |
Chemical Name | 1-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]thiourea | ||
Canonical SMILES | CC1=C(N=CN1)CSCCNC(=S)NC | ||
Formula | C9H16N4S2 | M.Wt | 244.38 |
Solubility | DMSO : 2.4 mg/mL (9.82 mM; Need ultrasonic and warming); H2O : 1.67 mg/mL (6.83 mM; ultrasonic and warming and heat to 60°C) | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 4.092 mL | 20.4599 mL | 40.9199 mL |
5 mM | 0.8184 mL | 4.092 mL | 8.184 mL |
10 mM | 0.4092 mL | 2.046 mL | 4.092 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *